<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1692">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738175</url>
  </required_header>
  <id_info>
    <org_study_id>AMG-COV-201-BR</org_study_id>
    <nct_id>NCT04738175</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19</brief_title>
  <official_title>A Randomized, Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will receive a single injection of 40, 100, or 200 mg COVI-AMG or placebo via IV&#xD;
      push.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive a single injection of 40, 100, or 200 mg COVI-AMG or placebo via IV&#xD;
      push. Subjects will be followed for 70 days after dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events by type, frequency, severity, and causality (safety)</measure>
    <time_frame>Randomization through study completion at Day 70</time_frame>
    <description>Safety as assessed by incidence of adverse events by type, frequency, severity, and causality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in viral shedding from Baseline to Day 15</measure>
    <time_frame>Randomization to Day 15</time_frame>
    <description>Changes in viral shedding from Baseline to Day 15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in viral shedding from Baseline to Day 8, 29, 43, and 70</measure>
    <time_frame>Randomization to Day 8, 29, 43, 70</time_frame>
    <description>Changes in viral shedding from Baseline to Day 8, 29, 43, and 70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to viral RNA negativity</measure>
    <time_frame>Randomization through study completion at Day 70</time_frame>
    <description>Time to viral RNA negativity using nasopharyngeal reverse transcription PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of symptoms</measure>
    <time_frame>Randomization through study completion at Day 70</time_frame>
    <description>Time to resolution of symptoms as assessed by the COVID-19 PRO instrument</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">209</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVI-AMG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg, 100 mg, or 200 mg of COVI-AMG will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVI-AMG</intervention_name>
    <description>COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)</description>
    <arm_group_label>COVI-AMG</arm_group_label>
    <other_name>STI-2020</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Diluent solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatient with recent COVID-19 diagnosis with mild or moderate symptoms lasting less&#xD;
             than 7 days prior to Screening and not requiring imminent hospitalization&#xD;
&#xD;
          -  No medical or psychiatric conditions that could put the subject at risk&#xD;
&#xD;
          -  Willing to follow contraception guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical signs of COVID-19 indicative of impending hospitalization&#xD;
&#xD;
          -  Documented infection in addition to COVID-19 that requires systemic treatment&#xD;
&#xD;
          -  Medical condition that could adversely impact safety, in the Investigator's opinion&#xD;
&#xD;
          -  Is or planning to be pregnant or lactating&#xD;
&#xD;
          -  Has participated, or is participating, in a clinical research study evaluating&#xD;
             COVID-19 convalescent plasma, monoclonal antibodies (mAbs) against SARS-CoV-2, or&#xD;
             intravenous immunoglobulin (IVIG) within 3 months or less than 5 half-lives of the&#xD;
             investigational product (whichever is longer) prior to the screening visit&#xD;
&#xD;
          -  Has received or will receive during study participation a vaccine for COVID-19&#xD;
&#xD;
          -  Has participated in clinical trial protocols in the last 12 months, unless the&#xD;
             Investigator believes that there may be a direct benefit to the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Royal, MD</last_name>
    <phone>(858) 203-4100</phone>
    <phone_ext>4146</phone_ext>
    <email>mroyal@sorrentotherapeutics.com</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid-19</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

